MedCity News

OCTOBER 27, 2022

GSK drug otilimab failed a Phase 3 test in rheumatoid arthritis. Though the antibody drug met the main goal in two other pivotal studies, GSK said the limited efficacy in the third study means the company will not seek regulatory approval.

Prospecting 94

Prospecting Biopharma Pharma 94

Pharmaceutical Technology

SEPTEMBER 13, 2022

The company provides strategic assistance and regulatory support to biopharma firms across the lifecycle of the product. The PharmaLex takeover will build upon the current European presence of AmerisourceBergen in pharmaceutical supply and biopharma manufacturer services expertise.

Biopharma 52

Biopharma Manufacturing Pharmaceutical manufacturing Consulting 52

MedCity News

NOVEMBER 22, 2023

With financing prospects dim and no one willing to take on its assets, Evelo is dissolving its business. Evelo Biosciences’ vision of using microbes to engage the gut and modulate immune responses remains unrealized.

Prospecting 107

Prospecting Biopharma Pharma 107

PM360

DECEMBER 20, 2023

With 2024 on the horizon, many in the biopharma space are taking stock of 2023 and what the current environment means for their potential success next year. Evaluate’s VC data show quarter-over-quarter drops in the number of biopharma companies raising private cash and in the amount of money raised.

Biopharma 111

Biopharma Pharma Marketing Management 111

The Marketing Advantage

FEBRUARY 26, 2024

Despite these challenges, the sales force is one of the most important tools a biopharma company has in driving disease awareness and reaching these too often underserved patients, requiring effective sales compensation planning and goal setting. So then how should goals be set for rare disease products?

Sales 52

Sales Consulting Prospecting Biopharma 52

Medico Reach

AUGUST 1, 2022

Whether you are a start-up looking for investment or are interested in working in venture capital (VC), the worldwide biopharma and MedTech industries are growing. In 2022, over $14 billion was funded in biopharma setup globally, and 37 major IPOs of VC-backed biotech company businesses raised a combined $4.2 CEO : Samuel Isaly.

Biopharma 52

Biopharma Healthcare Healthcare Specialization 52

MedCity News

MARCH 19, 2023

Prospective buyers can pick up Pear’s FDA-cleared products for substance use disorder, opioid use disorder, and insomnia. Pear Therapeutics isn’t meeting the commercialization goals for its prescription digital therapeutics, so it’s now seeking strategic alternatives for the business.

Prescription 96

Prescription Prospecting FDA Biopharma 96

MedCity News

JUNE 29, 2023

Eli Lilly is expanding its diabetes prospects by acquiring cell therapy developer Sigilon Therapeutics. The two companies are already partners in the development of a type 1 diabetes cell therapy currently in preclinical development.

Prospecting 81

Prospecting Biopharma Pharma 81

MedCity News

APRIL 17, 2023

The deal comes as Merck looks for drug prospects that could make up for revenue declines facing blockbuster seller Keytruda, which faces patent expirations in coming years. Merck is acquiring Prometheus Biosciences and a lead drug candidate in development for inflammatory bowel disorders.

Medicine 93

Medicine Prospecting Leads Biopharma 93

Clarivate

JULY 24, 2023

Biopharma and medtech brands made up a dozen of the Clarivate Top 100 New Brands for 2023, as the life science industries continued to show a muscular approach to protecting their intellectual property.

Pharma 52

Pharma Biopharma Prospecting Training 52

PM360

NOVEMBER 12, 2023

While the global biopharma industry retains its huge dependence on the U.S. This should, at least in theory, make them an appealing target for biopharma companies looking to expand beyond the hugely competitive markets of the U.S., market, emerging markets present great opportunities for biotech and pharmaceutical companies.

Marketing 59

Marketing Biopharma Government Pharma 59

pharmaphorum

DECEMBER 16, 2022

Last month, Astellas reported similar results in its SPOTLIGHT trial, which had largely the same design as GLOW, but replaced CAPOX with another chemo regimen called mFOLFOX6 , and with two positive phase 3 trials in the bag the drugmaker can now turn its attention to regulatory filings and the prospect of being first to market with a claudin 18.2

Leads 57

Leads Biopharma Prospecting Patients 57

pharmaphorum

DECEMBER 28, 2022

billion buyout of Principia Biopharma. While the partial hold may simply be a hiccup for InnoCare and Biogen’s programme, it does undermine prospects for orelabrutinib, which is one of several oral BTK inhibitors being developed for MS and other autoimmune diseases.

FDA 69

FDA Side effects Biopharma Prospecting 69

PM360

APRIL 7, 2023

Biopharma should pay special attention to this. Biopharma companies that bring patients together in-person can create a sense of belonging and support that is often missing in the digital realm. Social Connections and Mortality from all Causes and from Cardiovascular Disease: Prospective Evidence from Eastern Finland.”

Biopharma 52

Biopharma Patients Specialization Networking 52

PM360

APRIL 22, 2024

With an ever- increasing demand for their time and attention, it is more difficult than ever for biopharma representatives to convey their message to the physician audience. In one survey, only 12% of HCPs said they felt biopharma companies are very effective at providing HCP education and training to them.

Education 59

Education Physicians Healthcare Healthcare 59

The Marketing Advantage

JULY 10, 2023

We at The Marketing Advantage have been designing call plans based on sales, opportunity, potential, maintenance and growth for the biopharma industry for over 30 years. However, what we find is that in about three months, representatives who received only 5 or 6 super prospects wish that they had gotten 8.

Sales 40

Sales Consulting Specialization Prospecting 40

European Pharmaceutical Review

JULY 20, 2023

AAV development for cell and gene therapy The topic of product quality was introduced in a panel discussion on AAVs in gene therapy, which saw speakers address the obstacles and prospects concerning IND application through to commercialisation. In a separate dialogue, Dr Baghirzade agreed that the industry “is still evolving”.

Consulting 56

Consulting Side effects Manufacturing Safety 56

Clarivate

MAY 8, 2024

As companies face the prospect of major revenue challenges over the next few years, securing inorganic growth through strategic alliances is increasingly attractive. As a result, 2023 saw an upsurge in merger and acquisition (M&A) and deal activity.

Pharma 59

Pharma Biopharma Prospecting Competition 59

Zymewire

FEBRUARY 8, 2024

Skip to a topic Axonis' journey and purpose The impact of the economic client on emerging biopharma The place of Artificial Intelligence in drug development & discovery Working with NASA Relationships with CROs, CDMOs, and other service providers What made you want to start Axonis? sending neurons to space.

Competition 52

Competition Leads Patients Marketing 52

European Pharmaceutical Review

APRIL 30, 2024

What are the top three trends that you are seeing in the biopharma manufacturing space? Let’s talk about continuous biopharma manufacturing. Speaking of your biopharma clients, what are you hearing about their main priorities? I believe this is going to be an emerging trend in the market.

Manufacturing 76

Manufacturing Food and Drug Administration Biopharma Marketing 76

Clarivate

DECEMBER 6, 2022

In July 2022, ChristianaCare acquired the shuttered Jennersville Hospital from Tower Health, but plans to purchase four-hospital Crozer Health from for-profit Prospect Medical Holdings fell through in September 2022.

Networking 52

Networking Healthcare Healthcare Competition 52

European Pharmaceutical Review

OCTOBER 27, 2022

The report’s authors identified that nearly 36 percent of biopharma companies will be increasing their spending on outsourced R&D or biomanufacturing over the next 12 months. Average budgets for outsourcing at individual facilities also remain relatively steady, growing by a weighted average increase of 12.8 percent in 2022.

Biopharma 79

Biopharma Manufacturing Pharmacology Training 79

Clarivate

DECEMBER 14, 2023

A long winter for biotech financing: Capital scarcity is likely to continue as prospective investors and partners remain cautious, due to rising interest rates and concerns around externalities such as government initiatives to contain healthcare costs and global geopolitical conflicts.

Pharma 111

Pharma Pharmacology Government Healthcare 111

Clarivate

FEBRUARY 28, 2023

“A Hospital-Based Five-Year Prospective Study on the Prevalence of Leber’s Hereditary Optic Neuropathy with Genetic Confirmation.” . “Leber Hereditary Optic Neuropathy: Case Report and Literature Review.” ” Cureus; V.12; 4; 4/20/2020; DOI:10.7759/cureus.7745 7745 [4] Gowri P et al.

Prescription 98

Prescription Patients Pharmacology Healthcare 98

Clarivate

OCTOBER 7, 2021

Adjuvant camrelizumab combined with apatinib treatment after resection of hepatocellular carcinoma in CNLC II and III stage: A single-center prospective phase II trial. Abstract LBA52. Abstract 944P. The post Top oncology breakthroughs shared at ESMO 2021 appeared first on Clarivate.

Patients 91

Patients Safety Marketing Physicians 91

Pharmaceutical Technology

JUNE 20, 2023

At $48 a share for the South San Francisco,California-based biopharma, Lilly is paying a 40% premium on top of the 30-day average trading price. GlobalData is the parent company of Pharmaceutical Technology DICE’s novel oral therapeutic candidates positioned it as an attractive prospect for acquisition.

Prospecting 52

Prospecting Competition Biopharma Marketing 52

Pharmaceutical Technology

MAY 22, 2023

The result was a plethora of patient infringement lawsuits , with several cases being filed that included Moderna, Pfizer/BioNTech, Alnylam Pharmaceuticals, Arbutus Biopharma, and Genevant Sciences on different sides of the court. With the emergence of vaccines came accusations of technology encroachment amongst biotech companies.

Biopharma 116

Biopharma Prospecting Competition Pharmaceutical 116

Pharmaceutical Technology

MARCH 21, 2023

Vetter Pharma-Fertigung GmbH & Co KG is contracted for the parenteral manufacture and packaging for the vascular endothelial growth factor (VEGF) inhibitor, while Biogen and KBI Biopharma are producing the biologic API. Baxter Biopharma Solutions is contracted for the parenteral manufacture and packaging of Enhertu.

Manufacturing 59

Manufacturing Pharmaceutical Biopharma FDA 59

Pharmaceutical Technology

MAY 3, 2023

The proposed facility would play a vital role in fulfilling demand in the Asia Pacific region while representing an important hub for further biopharma industry development in South Korea.” We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects.

Government 52

Government Electronics Biopharma Prospecting 52

Pharmaceutical Technology

MARCH 31, 2023

In the panel, Melanie Senior, a biopharma reporter at Nature Biotech also pointed out reimbursement issues for obesity drugs. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects.

Training 52

Training Competition Biopharma Prospecting 52

Pharmaceutical Technology

MARCH 24, 2023

GC Biopharma is also running a Phase III trial for its live-attenuated vaccine GC-3107A to replace BCG. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects.

Pharma 64

Pharma Side effects Marketing Biopharma 64

Pharmaceutical Technology

JANUARY 15, 2023

Baxter Biopharma Solutions, Fareva SA, BSP Pharmaceuticals SpA, and Takeda Pharmaceuticals are manufacturing the parenteral portion of the ADC. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects.

Manufacturing 52

Manufacturing Pharmaceutical FDA Pharma 52

Pharmaceutical Technology

JUNE 16, 2023

Synthetic biology biopharma Biostar Pharma announced is ready to advance its utidelone injectable (UTD1) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), following approval from the US Food and Drug Administration (FDA) for the study.

FDA 52

FDA Food and Drug Administration Patients Marketing 52

Pharmaceutical Technology

APRIL 16, 2023

This is an exciting prospect: oncology, and immuno-therapy in particular, is a driving force behind biotech R&D, with new cancer therapies and molecules accounting for nearly 40% 1 of the industry’s development pipeline. SHL Medical’s Maggie 5.0

Medical 52

Medical Medicine Patients Manufacturing 52

Pharmaceutical Technology

FEBRUARY 27, 2023

Baxter Biopharma Solutions has been contracted for the ADC’s parenteral manufacture and packaging. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects.

Manufacturing 52

Manufacturing Pharmaceutical Pharma FDA 52

Pharmaceutical Technology

APRIL 27, 2023

The successful development and deployment of the mRNA-based COVID-19 vaccines has catalysed the biopharma industry and paved the way to expand this drug modality to new therapeutic areas. GlobalData pharmaceutical analysts project that RNA-based gene therapies for oncology will grow from zero in 2022 to $4.6 billion by 2028.

Manufacturing 52

Manufacturing Marketing Medicine Transportation 52